These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21144983)

  • 41. Interactions of anti-infectives: a review.
    Barcia E; Negro S
    Chemotherapy; 2005 Jul; 51(4):197-9. PubMed ID: 16006766
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibiotic use in critical illness.
    Stewart SD; Allen S
    J Vet Emerg Crit Care (San Antonio); 2019 May; 29(3):227-238. PubMed ID: 31021520
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents.
    Blot SI; Pea F; Lipman J
    Adv Drug Deliv Rev; 2014 Nov; 77():3-11. PubMed ID: 25038549
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is there a role for antibiotic cycling in the intensive care unit?
    Kollef MH
    Crit Care Med; 2001 Apr; 29(4 Suppl):N135-42. PubMed ID: 11292889
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics/pharmacodynamics characterization of combined antimicrobial agents: a real challenge and an urgent need.
    Couet W
    Clin Microbiol Infect; 2018 Jul; 24(7):687-688. PubMed ID: 29649606
    [No Abstract]   [Full Text] [Related]  

  • 46. Optimizing Pharmacokinetics-Pharmacodynamics of Antimicrobial Management in Patients with Sepsis: A Review.
    Phe K; Heil EL; Tam VH
    J Infect Dis; 2020 Jul; 222(Suppl 2):S132-S141. PubMed ID: 32691832
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adverse events caused by potential drug-drug interactions in an intensive care unit of a teaching hospital.
    Alvim MM; Silva LA; Leite IC; Silvério MS
    Rev Bras Ter Intensiva; 2015; 27(4):353-9. PubMed ID: 26761473
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quality measures of antimicrobial drug use.
    Gyssens IC
    Int J Antimicrob Agents; 2001 Jan; 17(1):9-19. PubMed ID: 11137643
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time.
    Dudley MN; Ambrose PG
    Curr Opin Microbiol; 2000 Oct; 3(5):515-21. PubMed ID: 11050452
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-infective therapy in intensive care units.
    Shah PM
    Infection; 1991; 19 Suppl 6():S316-9. PubMed ID: 1791076
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Therapeutic drug monitoring of antimicrobials.
    Roberts JA; Norris R; Paterson DL; Martin JH
    Br J Clin Pharmacol; 2012 Jan; 73(1):27-36. PubMed ID: 21831196
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.
    Moss DM; Marzolini C; Rajoli RK; Siccardi M
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1203-17. PubMed ID: 25872900
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rationalizing antimicrobial therapy in the ICU: a narrative review.
    Timsit JF; Bassetti M; Cremer O; Daikos G; de Waele J; Kallil A; Kipnis E; Kollef M; Laupland K; Paiva JA; Rodríguez-Baño J; Ruppé É; Salluh J; Taccone FS; Weiss E; Barbier F
    Intensive Care Med; 2019 Feb; 45(2):172-189. PubMed ID: 30659311
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimizing antimicrobial use: challenges, advances and opportunities.
    Rawson TM; Wilson RC; O'Hare D; Herrero P; Kambugu A; Lamorde M; Ellington M; Georgiou P; Cass A; Hope WW; Holmes AH
    Nat Rev Microbiol; 2021 Dec; 19(12):747-758. PubMed ID: 34158654
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimizing antimicrobial dosing in the critically ill patient.
    Goldberg J; Owens RC
    Curr Opin Crit Care; 2002 Oct; 8(5):435-40. PubMed ID: 12357112
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Utility of Microdialysis in Infectious Disease Drug Development and Dose Optimization.
    Deitchman AN; Heinrichs MT; Khaowroongrueng V; Jadhav SB; Derendorf H
    AAPS J; 2017 Mar; 19(2):334-342. PubMed ID: 27943149
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimal antimicrobial therapy: the balance of potency and exposure.
    Tillotson GS; Doern GV; Blondeau JM
    Expert Opin Investig Drugs; 2006 Apr; 15(4):335-7. PubMed ID: 16548783
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quinolone interactions with divalent or trivalent cations: have you checked the medication administration report lately?
    Redmond AM; Norwood JM; Amarshi N; Self T
    South Med J; 2003 Sep; 96(9):941-2. PubMed ID: 14513999
    [No Abstract]   [Full Text] [Related]  

  • 59. Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.
    Gonzalez D; Schmidt S; Derendorf H
    Clin Microbiol Rev; 2013 Apr; 26(2):274-88. PubMed ID: 23554417
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antimicrobial agents, drug adverse reactions and interactions, and cancer.
    Millan X; Muggia V; Ostrowsky B
    Cancer Treat Res; 2014; 161():413-62. PubMed ID: 24706233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.